The rapid advancements in biomedical technologies have brought both opportunities and challenges, necessitating robust regulatory frameworks to ensure safety, efficacy, and ethical use. This paper explores the evolving landscape of regulatory responses to emerging biomedical technologies, including genetic engineering, nanomedicine, and artificial intelligence in healthcare. It discusses the historical context of regulatory frameworks and their limitations in adapting to innovative technologies. Furthermore, the paper assesses the effectiveness of existing regulatory mechanisms, such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in the European Union, in managing risks associated with these technologies. The analysis highlights the need for a dynamic and inclusive approach to regulation, involving stakeholders from various backgrounds to ensure that emerging biomedical technologies are developed and implemented responsibly. The paper concludes by emphasizing the importance of interdisciplinary collaboration and international cooperation in shaping effective regulatory responses to the ever-changing biomedical landscape.
Anderson, E. Regulatory Responses to Emerging Biomedical Technologies. Frontiers of Law & Policy Research, 2023, 5, 43. https://doi.org/10.69610/j.flpr.20231016
AMA Style
Anderson E. Regulatory Responses to Emerging Biomedical Technologies. Frontiers of Law & Policy Research; 2023, 5(2):43. https://doi.org/10.69610/j.flpr.20231016
Chicago/Turabian Style
Anderson, Emily 2023. "Regulatory Responses to Emerging Biomedical Technologies" Frontiers of Law & Policy Research 5, no.2:43. https://doi.org/10.69610/j.flpr.20231016
APA style
Anderson, E. (2023). Regulatory Responses to Emerging Biomedical Technologies. Frontiers of Law & Policy Research, 5(2), 43. https://doi.org/10.69610/j.flpr.20231016
Article Metrics
Article Access Statistics
References
Burbules, N. C., & Callister, T. A. (2000). Watch IT: The Risks and Promises of Information Technologies for Education. Westview Press.
European Medicines Agency (EMA). (2018). Overview of the regulatory framework. Retrieved from https://www.ema.europa.eu/en/documents/overview/regulatory-framework-overview_en.pdf
Taylor, D. G., & Theoharides, T. C. (2012). Regulatory Challenges in Nanomedicine. Journal of Nanoparticle Research, 14(1), 1-10.
Oyserman, D. A., & Dwyer, S. H. (2010). A Call for Patient Involvement in nanomedicine research. Accounts of Chemical Research, 43(5), 695-701.
European Union. (2004). Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 on medicinal products for human use. Official Journal of the European Union, L136, 1-15.
O'Doherty, M., & Smith, R. (2009). The role of patient and public involvement in health research. Patient Education and Counseling, 75(1), 9-13.
Nuffield Council on Bioethics. (2012). Public Health Genomics. London: Nuffield Council on Bioethics.
European Medicines Agency. (2017). Ethical considerations for medicines regulation. Retrieved from https://www.ema.europa.eu/en/documents/overview/ethical-considerations-medicines-regulation_en.pdf
European Commission. (2017). EU-US Regulatory Cooperation: Proposal for a Joint Declaration of Intent. Retrieved from https://ec.europa.eu/health/sites/health/files/pharmaceuticals/docs/2017_11_14_eu_us_regulatory_cooperation_en.pdf
World Health Organization. (2011). Global Strategy for Safe, Effective, and. Retrieved from https://www.who.int/selection_and_research/health_systems/pharmacists/Global_Strategy_for_Safe_Effective_and_Cost-Effective_Use_of_Medicines.pdf